Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of...

|About: Abbott Laboratories (ABT)|By:, SA News Editor

Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR)